The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling

Pharmacology Research and Perspectives

Volumn 1, Issue 2, 2013, Pages

  Atanes, Patricio ^a   Lacivita, Enza ^b   Rodríguez, Javier ^a   Brea, José ^a   Burgueño, Javier ^c   Vela, José Miguel ^c   Cadavid, María Isabel ^a   Loza, María Isabel ^a   Leopoldo, Marcello ^b   Castro, Marián ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF BARI   (Italy)

^c Drug Discovery and Preclinical Development   (Spain)

Author keywords

arylpiperazine derivative; cAMP signaling; HEK293 cells; insurmountable antagonism; irreversible inhibition; long lasting inhibition; LP 211; preincubation washout experiments; Schild analysis; serotonin 5 HT7 receptors; 3H SB 269970 binding

Indexed keywords

EID: 84939996184     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.13     Document Type: Article

References (45)

1. Adriani W, Travaglini D, Lacivita E, Saso L, Leopoldo M, Laviola G (2012). Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice. Neuropharmacology 62: 833–842.
2. Andressen KW, Norum JH, Levy FO, Krobert KA (2006). Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol Pharmacol 69: 207–215.
3. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A (2011). Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.
4. Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, et al. (2012). Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 342: 429–440.
5. Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, et al. (2009). 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain 141: 239–247.
6. Bruheim S, Krobert KA, Andressen KW, Levy FO (2003). Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs. Receptors Channels 9: 107–116.
7. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB (2013). Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 70: 211–217.
8. Costa L, Spatuzza M, D'Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, et al. (2012). Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 72: 924–933.
9. Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56: 441–451.
10. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, et al. (2000). Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 130: 539–548.
11. Hedlund PB (2009). The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 206: 345–354.
12. Hedlund PB, Sutcliffe JG (2004). Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25: 481–486.
13. Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, et al. (2010). LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor. Neurosci Lett 481: 12–16.
14. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME (2012). A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 73: 953–959.
15. Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533–554.
16. Iceta R, Mesonero JE, Aramayona JJ, Alcalde AI (2009). Expression of 5-HT1A and 5-HT7 receptors in Caco-2 cells and their role in the regulation of serotonin transporter activity. J Physiol Pharmacol 60: 157–164.
17. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG (2012). ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757–1768. doi: 10.1021/ci3001277
18. Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM (1997). Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol 122: 126–132.
19. Kenakin TP (2009). A pharmacology primer. theory, applications, and methods. 3rd ed. Elsevier Academic Press. San Diego, CA.
20. Klein MT, Teitler M (2011). Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect. Br J Pharmacol 162: 1843–1854.
21. Krobert KA, Andressen KW, Levy FO (2006). Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor. Eur J Pharmacol 532: 1–10.
22. Lacivita E, Patarnello D, Stroth N, Caroli A, Niso M, Contino M, et al. (2012). Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo. J Med Chem 55: 6375–6380.
23. Lemoine L, Andries J, Le Bars D, Billard T, Zimmer L (2011). Comparison of 4 radiolabeled antagonists for serotonin 5-HT(7) receptor neuroimaging: toward the first PET radiotracer. J Nucl Med 52: 1811–1818.
24. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, et al. (2004a). Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J Med Chem 47: 6616–6624.
25. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Perrone R, et al. (2004b). Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. J Pharm Pharmacol 56: 247–255.
26. Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (2007). Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem 50: 4214–4221.
27. Leopoldo M, Lacivita E, De Giorgio P, Fracasso C, Guzzetti S, Caccia S, et al. (2008). Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem 51: 5813–5822.
28. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB (2011). Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 129: 120–148.
29. Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, et al. (2000). A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970). J Med Chem 43: 342–345.
30. Martínez-García E, Leopoldo M, Lacivita E, Terrón JA (2011). Increase of capsaicin-induced trigeminal Fos-like immunoreactivity by 5-HT(7) receptors. Headache 51: 1511–1519.
31. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P (2011). Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. Mol Neurobiol 43: 228–253.
32. Meltzer HY, Massey BW (2011). The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11: 59–67.
33. Moore CA, Milano SK, Benovic JL (2007). Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69: 451–482.
34. Perrone R, Berardi F, Colabufo NA, Lacivita E, Leopoldo M, Tortorella V (2003). Synthesis and structure-affinity relationships of 1-[omega-(4-aryl-1-piperazinyl)alkyl]-1-aryl ketones as 5-HT(7) receptor ligands. J Med Chem 46: 646–649.
35. Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (2007). 5-HT7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev. Med. Chem. 7: 945–960.
36. Regard JB, Sato IT, Coughlin SR (2008). Anatomical profiling of G protein-coupled receptor expression. Cell 135: 561–571.
37. Reynolds EE, Molinoff PB (1986). Down regulation of beta adrenergic receptors in S49 lymphoma cells induced by atypical agonists. J Pharmacol Exp Ther 239: 654–660.
38. Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (2006). Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70: 1264–1270.
39. Sneddon WB, Magyar CE, Willick GE, Syme CA, Galbiati F, Bisello A, et al. (2004). Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. Endocrinology 145: 2815–2823.
40. Stahl SM (2010). The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry 71: 1414–1415.
41. Thomas DR, Atkinson PJ, Hastie PG, Roberts JC, Middlemiss DN, Price GW (2000). [(3)H]-SB-269970–A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol 130: 409–417.
42. Tokarski K, Zelek-Molik A, Duszynska B, Satała G, Bobula B, Kusek M, et al. (2012). Acute and repeated treatment with the 5-HT7 receptor antagonist SB 269970 induces functional desensitization of 5-HT7 receptors in rat hippocampus. Pharmacol. Rep. 64: 256–265.
43. Toohey N, Klein MT, Knight J, Smith C, Teitler M (2009). Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol Pharmacol 76: 552–559.
44. Tsao P, von Zastrow M (2000). Downregulation of G protein-coupled receptors. Curr Opin Neurobiol 10: 365–369.
45. Varin T, Gutiérrez-de-Terán H, Castro M, Brea J, Fabis F, Dauphin F, et al. (2010). Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists. Br J Pharmacol 159: 1069–1081.